Abstract Glycogen synthase kinase‐3 (GSK3) is an important signalling protein in the brain
and modulates different forms of synaptic plasticity. Neuronal functions of GSK3 are typically …

Glycogen-synthase kinase-3 (GSK-3) plays a central role in Alzheimer's disease (AD). It is
involved in the hyper-phosphorylation of Tau and the increased production of β-amyloid …

The toxicity of amyloid-beta (Aβ) is strongly associated with Alzheimer's disease (AD), which
has a high incidence in the elderly worldwide. Recent evidence showed that alteration in the …

Aβ peptide accumulation is thought to be the primary event in the pathogenesis of
Alzheimer's disease (AD), with downstream neurotoxic effects including the …

It is becoming increasingly clear that aberrant neuronal activity can be the cause and the
result of amyloid beta production. Synaptic activation facilitates non-amyloidogenic …

Synaptic dysfunction during early stages of Alzheimer's disease (AD) is triggered by soluble
amyloid-ß (Aß) oligomers that interact with NMDA receptors (NMDARs). We previously …

Phosphorylation is the most common post‐translational modification of cellular proteins,
essential for most physiological functions. Deregulation of phosphorylation has been …

Abstract Glycogen synthase kinase-3 (GSK-3) is a constitutively active kinase, involved in
regulation of multiple physiological processes. In brain, changes in GSK-3 signaling are …

Cyclin-dependent kinase 5 (cdk5) and glycogen synthase kinase 3β (GSK3β) have been
implicated in pathogenic processes associated with Alzheimer9s disease because both …

Glycogen synthase kinase 3β (GSK‐3β) is an important regulatory kinase involved in
multiple processes such as metabolic control, embryonic development, cell death, and …